Imunon (NASDAQ:IMNN) Upgraded to “Strong-Buy” at EF Hutton Acquisition Co. I

EF Hutton Acquisition Co. I upgraded shares of Imunon (NASDAQ:IMNN) to a strong-buy rating in a research note released on Monday, Zacks.com reports.

Separately, HC Wainwright reissued a buy rating and set a $14.00 price objective on shares of Imunon in a report on Thursday, August 15th.

Imunon Stock Performance

NASDAQ IMNN opened at $1.01 on Monday. Imunon has a 1-year low of $0.48 and a 1-year high of $3.65. The company has a 50 day moving average of $1.19 and a 200-day moving average of $1.26. The firm has a market cap of $9.50 million, a price-to-earnings ratio of -0.50 and a beta of 2.13.

Imunon (NASDAQ:IMNN) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.51) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.04. On average, analysts forecast that Imunon will post -1.71 earnings per share for the current year.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.